Dr. Jeffrey Stephen Crespin, MD

Dr. Crespin practices at Westside GI Center in New York, New York.

Dr. Crespin's NPI, 1164421277, was assigned on July 20, 2005. Dr. Crespin graduated from WashU Medicine in 1993. Dr. Crespin holds New York license 213987.

Dr. Crespin's primary practice is Westside GI Center, at 619 West 54th Street, 8th Floor, New York, NY 10019. The practice phone is (646) 878-2350.

Dr. Crespin's primary practice is Westside GI Center in New York, New York. Dr. Crespin is also affiliated with Lenox Hill Hospital. The medical group on file is SBH Physicians. Dmand AI also links Dr. Crespin to 1 more hospital, 1 physician office and 1 ambulatory surgery center, each named with a free account. Dr. Crespin's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Crespin practices, 5 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Crespin's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Crespin is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Crespin's licenses on file in 3 states: New York, Minnesota and Illinois.

Dmand AI lists acid reflux, colonoscopy, gastrointestinal bleeding, irritable bowel syndrome (IBS) and upper GI endoscopy among the conditions Dr. Crespin treats.

CMS data shows 384 Medicare services from Dr. Crespin across 11 procedure codes in 2024, for 109 Medicare patients. Medicare paid $25,004 for them.

CMS counts 109 Medicare patients who saw Dr. Crespin in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 25% are also on Medicaid. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Crespin's median patient age at 48, with 41% women.

In 2024, Dr. Crespin wrote 392 Medicare Part D claims for 104 patients. 85% of them were for generic drugs. CMS names the drug for 164 of them, across 11 drugs with 11 or more claims each, at $5,570 in total drug cost. In 2023, CMS named 131 claims across 8 drugs.

Dr. Crespin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 69 procedures of colonoscopy by Dr. Crespin, more than 71% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Crespin.

Dmand AI links Dr. Crespin to 4 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Eosinophilic Esophagitis, Esophagitis and Colitis, Ulcerative. Celgene sponsors the most, 2. Open Payments lists research payments to Dr. Crespin that name 2 trials.

CMS Open Payments shows 853 general payments to Dr. Crespin from 54 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 55% of the total. Endo Pharmaceuticals Inc. paid the most, $8,679. It also lists 2 research payments totaling $8,277 in 2021, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Crespin, most recently CMS Stage 1 EHR in 2013.

Dr. Crespin graduated from WashU Medicine in 1993. Dr. Crespin is a member of ACG, ACP, AGA and AMA.

Dr. Crespin is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.